Skip to content

Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease

Robotic-Assisted Versus Conventional Bronchoscopy for Cryobiopsy in the Diagnosis of Interstitial Lung Disease: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07500818
Acronym
RAB-ILD-RCT
Enrollment
30
Registered
2026-03-30
Start date
2026-02-01
Completion date
2027-09-01
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease (ILD), Lung Biopsy

Keywords

Robotic-assisted Bronchoscopy, Cryobiopsy, CBCT, Interventional Pulmonology, Interstitial Lung Disease

Brief summary

Interstitial lung disease (ILD) often requires histopathological confirmation when high-resolution computed tomography (HRCT) findings are inconclusive. Transbronchial lung cryobiopsy has emerged as a less invasive alternative to surgical lung biopsy, but diagnostic yield remains variable and dependent on biopsy location and procedural precision. Robotic-assisted bronchoscopy (RAB) combined with cone-beam computed tomography (CBCT) may allow more precise navigation to target lung segments and potentially improve biopsy quality and diagnostic yield. This multi-center, investigator-initiated randomized controlled trial will compare conventional bronchoscopy with 2D fluoroscopy guidance versus robotic-assisted bronchoscopy with CBCT guidance for transbronchial lung cryobiopsy in patients undergoing diagnostic evaluation for suspected interstitial lung disease. Participants will be randomized in a 1:1 ratio to undergo either conventional bronchoscopy or robotic-assisted bronchoscopy. In both groups, four cryobiopsies will be obtained from two lung lobes using a 1.7 mm cryoprobe (en-bloc removal for both study arms). The primary endpoint is the rate of definitive histological diagnosis as determined by a blinded multidisciplinary ILD board.

Detailed description

Histopathologic evaluation remains a key component in the diagnosis of many interstitial lung diseases when radiological and clinical findings are inconclusive. Transbronchial lung cryobiopsy (TBLC) has increasingly replaced surgical lung biopsy due to its lower morbidity, but diagnostic yield varies widely depending on procedural technique and sampling accuracy. Robotic-assisted bronchoscopy (RAB) offers improved catheter stability and precise navigation to peripheral lung regions. When combined with cone-beam CT (CBCT), RAB allows real-time confirmation of biopsy location, potentially improving sampling of diagnostically relevant lung parenchyma while avoiding bronchial structures. However, the incremental diagnostic value of RAB combined with CBCT compared with conventional bronchoscopy using fluoroscopy guidance has not yet been evaluated in a randomized controlled trial. This investigator-initiated trial aims to determine whether robotic-assisted bronchoscopy with CBCT improves the rate of definitive histological diagnosis compared with conventional bronchoscopy. Participants will be randomized 1:1 to either: * Conventional bronchoscopy with fluoroscopy-guided cryobiopsy * Robotic-assisted bronchoscopy with CBCT-guided cryobiopsy In both arms, four biopsies will be obtained from two different lung lobes using a 1.7 mm cryoprobe. Histological specimens will be evaluated by a blinded multidisciplinary ILD board.

Interventions

PROCEDURERobotic-Assisted Bronchoscopy With Cone-Beam CT Guidance

Robotic-assisted bronchoscopy using a shape-sensing robotic platform with cone-beam CT confirmation of biopsy location. Four cryobiopsies will be obtained from two lung lobes using a 1.7 mm cryoprobe.

PROCEDUREConventional Bronchoscopy With Fluoroscopy Guidance

Flexible bronchoscopy with 2D fluoroscopy guidance. Four cryobiopsies will be obtained from two lung lobes using a 1.7 mm cryoprobe.

Sponsors

University of Zurich
Lead SponsorOTHER
Cantonal Hospital of Lucerne, Switzerland
CollaboratorUNKNOWN
University Hospital, Zürich
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Clinical suspicion of interstitial lung disease requiring histological confirmation * Non-diagnostic HRCT pattern (e.g. probable UIP or indeterminate pattern) * Candidate for transbronchial lung cryobiopsy * Ability to provide informed consent

Exclusion criteria

* Definite UIP pattern on HRCT * Severe pulmonary hypertension * Severe hypoxemia contraindicating bronchoscopy * Coagulopathy or contraindication to biopsy * Pregnancy * Inability to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
Histological DiagnosisPerioperative/PeriproceduralRate of Definitive Histological Diagnosis

Secondary

MeasureTime frameDescription
Biopsy SizePerioperative/PeriproceduralMean cross-sectional area of cryobiopsy specimens measured in mm².
Tissue Composition of BiopsiesPerioperative/PeriproceduralPercentage composition of biopsy specimens including: * Lung parenchyma * Bronchial tissue * Bronchiolar tissue
Safety CompositeUp to 24 hours post procedureComposite safety endpoint including: * Clinically significant bleeding * Pneumothorax requiring intervention * Transfer to intensive care unit

Countries

Switzerland

Contacts

CONTACTThomas Gaisl, MD MPH PhD
thomas.gaisl@uzh.ch+41762318339

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026